Latvia

Population (January 2013): 2,023,825
Human development Index (2013): LV: 0.810

HAV vaccine recommendations:
HAV vaccination is not included in the national childhood immunization programme. Vaccination is recommended for:
1. Travellers to endemic areas
2. People infected with HBV or HCV
3. For outbreak control.

Seroprevalence studies by quality score:
- score 0: 0 studies
- score 1: 0 studies
- score 2: 0 studies

Seroprevalence studies timeframe:
- No study on HAV seroprevalence could be found on Latvian population.

Latvia_Table 1. Hepatitis A seroprevalence level by time period

<table>
<thead>
<tr>
<th>Time Period</th>
<th>Very low endemicity</th>
<th>Low endemicity</th>
<th>Intermediate endemicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>1975–1989</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1990–1999</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2000–2013</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Available incidence data from 1990 shows a steady decrease from more than 250 cases per 100,000 to 5 cases per 100,000 in 2001. Reported incidence in TESSy from 2006 to 2012 widely oscillates from less than 1 case per 100,000 in 2007 and 2012 to more than 100 cases per 100,000 in 2008 and 2009 (Latvia_Figure 2).

Latvia_Figure 1. Reported incidence of hepatitis A in Latvia, 1990–2013

Bibliography